|Articles|October 15, 2001
- BioPharm International-10-01-2001
- Volume 14
- Issue 10
Inside Washington: Crisis and Costs Grip Biotech Industry
Author(s)Jill Wechsler
by Jill Wechsler Terrorist attack may postpone health policy legislation but encourage antibioterrorism initiatives.
Advertisement
Articles in this issue
about 24 years ago
Qualification of Network Components and Validation of Networked Systemsabout 24 years ago
Statistical Tools for Setting In-Process Acceptance Criteriaabout 24 years ago
Managing Your Career: Recruiter-Proof Your Organizationabout 24 years ago
Outsourcing OutlookNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Implementing Automation and Flexible Design for Allogeneic Manufacturing
2
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
3
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
4
Emerging siRNA Platform Offers New Metabolic Disorder Therapies
5
